EP3644953A1

EP3644953A1 - Use of n-(4-amino-2-methylquinoline-6-yl)-2-((4-ethylphenoxy)methyl)benzamide for producing cosmetic or dermatological preparations for the treatment and/or prophylaxis of symptoms of intrinsic and/or extrinsic skin aging and for the treatment and/or prophylaxis of damaging effects of ultraviolet radiation on the skin

Info

Publication number: EP3644953A1
Application number: EP18730659.2A
Authority: EP
Inventors: Wilfried Siefken; Jörn Hendrik Reuter
Original assignee: Beiersdorf AG
Current assignee: Beiersdorf AG
Priority date: 2017-07-24
Filing date: 2018-05-25
Publication date: 2020-05-06
Also published as: US20210145723A1; DE102017212649A1; WO2019020248A1

Abstract

The invention relates to the use of N-(4-amino-2-methylquinoline-6-yl)-2-((4-ethylphenoxy)methyl)benzamide for producing cosmetic or dermatological preparations for the treatment and/or prophylaxis of symptoms of intrinsic and/or extrinsic skin aging and for the treatment and/or prophylaxis of damaging effects of ultraviolet radiation on the skin.

Description

description

Use of N- (4-amino-2-methylquinolin-6-yl) -2 - ((4-ethylphenoxy) methyl) benzamide for the preparation of cosmetic or dermatological preparations for the treatment and / or prophylaxis of the symptoms of intrinsic and / or extrinsic Skin aging and the treatment and prophylaxis of the harmful effects of ultraviolet radiation on the skin

The present invention relates to cosmetic or dermatological preparations containing N- (4-amino-2-methylquinolin-6-yl) -2 - ((4-ethylphenoxy) methyl) benzamide for the care and protection of the skin, in particular the sensitive skin as well as especially emphasizing the skin aged or aged by intrinsic and / or extrinsic factors as well as the use of such agents and combinations of such agents in the field of cosmetic and dermatological skin care.

Cosmetic skin care primarily means that the natural function of the skin is strengthened or restored as a barrier against environmental influences (eg dirt, chemicals, microorganisms) and against the loss of endogenous substances (eg water, natural fats, electrolytes) ,

If this function is disturbed, it may lead to increased absorption of toxic or allergenic substances or the infestation of microorganisms and as a result to toxic or allergic skin reactions.

In the case of old skin, for example, the regenerative renewal slows down, in particular, the water-binding capacity of the horny layer decreases. It therefore becomes inflexible, dry and cracked ("physiologically" dry skin). A barrier damage is the result.

The skin becomes susceptible to negative environmental influences such as the invasion of microorganisms, Toxins and allergens. As a result, even toxic or allergic skin reactions may occur.

In the case of pathologically dry and sensitive skin, barrier damage is a priori. Epidermal intercellular lipids are formed incorrectly or in insufficient quantity or composition. The consequence is an increased permeability of the horny layer and insufficient protection of the skin from loss of hygroscopic substances and water.

The barrier effect of the skin can be quantified by determining transepidermal water loss (TEWL). It is the evaporation of water from the inside of the body without the inclusion of water loss during sweating. The determination of the TEWL value has proven to be extraordinarily informative and can be used for the diagnosis of chapped or chapped skin, for the determination of the compatibility of chemically different surfactants and the like.

Chronic skin aging is e.g. caused by endogenous, genetically determined factors. In epidermis and dermis, age-related e. on the following structural damage and dysfunctions, which may also fall under the term "senile xerosis": a) dryness, roughness and formation of dryness lines,

b) itching and

c) Reduced fatty acid regurgitation (e.g., after washing).

Exogenous factors such as UV light and chemical noxae can be cumulatively effective and e.g. accelerate or supplement endogenous aging processes. In epidermis and dermis, exogenous factors occur, e.g. on the following structural damage and dysfunction in the skin that go beyond the extent and quality of the damage caused by chronological aging: d) visible vascular dilations (telangiectasias, cuperosis);

e) slackness and formation of wrinkles; f) local hyper-, hypo- and false pigmentation (eg age spots) and g) increased susceptibility to mechanical stress (eg cracking).

The present invention relates in particular to products for the care of naturally aged skin, as well as for the treatment of the consequential damages of photoageing, in particular of the phenomena listed under a) to g).

Products for the care of aged skin are known per se. They contain e.g. Retinoids (vitamin A acid and / or derivatives thereof) or vitamin A and / or its derivatives. Their effect on the structural damage, however, is limited in scope. In addition, there are significant difficulties in product development in stabilizing the active ingredients sufficiently against oxidative degradation. In addition, the use of vitamin A acid-containing products often causes severe erythematous skin irritation. Retinoids can therefore only be used in low concentrations.

In particular, the present invention relates to cosmetic preparations with effective protection against harmful oxidation processes in the skin, but also for the protection of cosmetic preparations themselves or for the protection of the components of cosmetic preparations from harmful oxidation processes.

The present invention further relates to antioxidants, preferably those which are used in skin-care cosmetic or dermatological preparations. In particular, the invention also relates to cosmetic and dermatological preparations containing such antioxidants. In a preferred embodiment, the present invention relates to cosmetic and dermatological preparations for the prophylaxis and treatment of cosmetic or dermatological lesions, e.g. Skin aging, especially skin aging caused by oxidative processes.

Furthermore, the present invention relates to active ingredients and preparations containing such active ingredients, for the cosmetic and dermatological treatment or prophylaxis of erythematous, inflammatory, allergic or autoimmune-reactive phenomena, in particular dermatoses. In a further advantageous embodiment, the present invention relates to combinations of active substances and preparations which serve for the prophylaxis and treatment of photosensitive skin, in particular photodermatoses.

The damaging effect of the ultraviolet part of solar radiation on the skin is well known. While rays having a wavelength smaller than 290 nm (the so-called UVC region) are absorbed by the ozone layer in the earth's atmosphere, rays in the range between 290 nm and 320 nm, the so-called UVB region, cause erythema simple sunburn or even more or less severe burns.

As a maximum of the erythema efficiency of sunlight, the narrower range around 308 nm is given.

For protection against UVB radiation, numerous compounds are known which are derivatives of 3-benzylidene camphor, 4-aminobenzoic acid, cinnamic acid, salicylic acid, benzophenone and also of 2-phenylbenzimidazole.

Also for the range between about 320 nm and about 400 nm, the so-called UVA range, it is important to have available filter substances, since its rays can cause reactions in photosensitive skin. It has been proven that UVA radiation leads to damage to the elastic and collagenous fibers of the connective tissue, which causes the skin to age prematurely, and that it is to be regarded as the cause of numerous phototoxic and photoallergic reactions. The damaging influence of UVB radiation can be amplified by UVA radiation.

For protection against the rays of the UVA range, therefore, certain derivatives of the dibenzoylmethane are used whose photostability (Int. J. Cosm. Science 10, 53 (1988)) is not given sufficiently.

However, the UV radiation can also lead to photochemical reactions, in which case the photochemical reaction products intervene in the skin metabolism. Predominantly, such photochemical reaction products are free-radical compounds, for example hydroxyl radicals, singlet oxygen. Undefined radical photoproducts, which are formed in the skin itself, can also show uncontrolled sequelae due to their high reactivity. But also singlet oxygen, a non-radical excited state of the oxygen molecule can occur on UV irradiation, as well as short-lived epoxides and many others. Singlet oxygen, for example, is distinguished from the normally present triplet oxygen (radical ground state) by increased reactivity. However, there are also excited, reactive (radical) triplet states of the oxygen molecule.

Furthermore, UV radiation counts as ionizing radiation. Thus, there is a risk that ionic species may also be formed upon UV exposure, which in turn may oxidatively interfere with the biochemical processes.

In order to prevent these reactions, additional antioxidants and / or radical scavengers can be incorporated in the cosmetic or dermatological formulations.

It has already been proposed to use vitamin E, a substance with known antioxidant activity in sunscreen formulations, yet here again, the effect achieved lags far behind the hoped for.

The object of the invention was therefore also to provide cosmetic, dermatological and pharmaceutical active ingredients and preparations as well as sunscreen formulations which serve for the prophylaxis and treatment of photosensitive skin, in particular photodermatoses, preferably PLD.

Other names for the polymorphic light dermatosis are PLD, PLE, Mallorca acne and a variety of other names, as in the literature (eg A. Voeickel et al, Zentralblatt skin and venereal diseases (1989), 156, p.2), are indicated.

Mainly antioxidants are used as protective substances against spoilage of preparations containing them. Nevertheless, it is known that undesirable oxidation processes can also occur in human and animal skin. Such processes play an essential role in skin aging.

In the article "Skin Diseases Associated with Oxidative Injury" in "Oxidative Stress in Dermatology", p. 323 et seq. (Marcel Decker Inc., New York, Basel, Hong Kong, publishers: Jürgen Fuchs, Frankfurt, and Lester Packer, Berkeley, California), oxidative damage to the skin and its nearer causes are listed.

Also, for the purpose of preventing such reactions, antioxidants and / or radical scavengers may additionally be incorporated into cosmetic or dermatological formulations.

Although some antioxidants and radical scavengers are known. For example, it has already been proposed in US Pat. Nos. 4,144,325 and 4,248,861 as well as numerous other documents to use vitamin E, a substance with known antioxidant activity in sunscreen formulations, but the effect achieved here also remains far behind the hoped-for effect.

The object of the present invention was therefore to find ways that avoid the disadvantages of the prior art. In particular, the effect of repairing the damage associated with endogenous, chronological and exogenous skin aging and the prophylaxis should be permanent, sustainable and without the risk of side effects.

According to the invention, the drawbacks of the prior art are eliminated by the use of N- (4-amino-2-methylquinolin-6-yl) -2 - ((4-ethylphenoxy) methyl) benzamide for the preparation of cosmetic or dermatological preparations for the treatment and or prophylaxis of the symptoms of intrinsic and / or extrinsic skin aging, and for the treatment and prophylaxis of the harmful effects of ultraviolet radiation on the skin.

Cosmetic or dermatological preparations according to the invention containing N- (4-amino-2-methylquinolin-6-yl) -2 - ((4-ethylphenoxy) methyl) benzamide are extremely satisfactory preparations in every respect. It was not foreseeable for the skilled person that the preparations according to the invention better maintain or restore the barrier properties of the skin, better counteract skin dehydration,

work better against pigmentation disorders,

Act better against aging skin and

protect the skin better from environmental influences

as the preparations of the prior art.

When using the active compound combinations according to the invention or cosmetic or topical dermatological preparations with an effective content of active compound combinations used according to the invention, surprisingly an effective treatment, but also a prophylaxis

of deficient, sensitive or hypoactive skin conditions or deficient, sensitive or hypoactive states of skin appendages

of premature aging of the skin (e.g., wrinkles, age spots, telangiectasias) and / or cutaneous appendages,

of environmental factors (smoking, smog, reactive oxygen species, free radicals) and in particular light-induced negative changes in the skin and the appendages.

of light-induced skin damage

of pigmentation disorders,

from itching,

dry skin conditions and corneal barrier disorders,

from hair loss and for improved hair growth

of inflammatory skin conditions as well as atopic eczema, seborrheic eczema, polymorphic photodermatosis, psoriasis, vitiligo

possible. The active ingredient according to the invention or cosmetic or topical dermatological preparations with an effective content of the active ingredient according to the invention, however, also serves in a surprising manner

to soothe sensitive or irritated skin

for the stimulation of collagen, hyaluronic acid, elastin synthesis

to stimulate ceramide synthesis of the skin

to stimulate intracellular DNA synthesis, especially in deficient or hypoactive skin conditions. to increase the cell renewal and regeneration of the skin

to increase the skin's own protective and repair mechanisms (eg for dysfunctional enzymes, DNA, lipids, proteins)

for the pre- and post-treatment of topical application of laser and Abschleifbehandlungen z. As the reduction of skin wrinkles and scars serve to counteract the resulting skin irritation and promote the regeneration processes in the injured skin.

N- (4-amino-2-methylquinolin-6-yl) -2 - ((4-ethylphenoxy) methyl) benzamide is characterized by the structural formula

Cosmetic or dermatological preparations according to the invention preferably contain 0.001-10% by weight, particularly preferably 0.01-1% by weight, of N- (4-amino-2-methylquinolin-6-yl) -2- (( 4-ethylphenoxy) methyl) benzamide, based on the total composition of the preparations. The preparations according to the invention advantageously contain substances that absorb UV radiation in the UV-A and / or UV-B range, wherein the total amount of the filter substances z. From 0.1% to 40% by weight, preferably from 1 to 30% by weight, in particular from 3 to 20% by weight, based on the total weight of the preparations, in order to provide cosmetic preparations, which protect the hair or the skin from the entire range of ultraviolet radiation. They can also serve as a sunscreen for hair or skin.

The UV-B filters may be oil-soluble or water-soluble. Advantageous oil-soluble UV-B filter substances are z. B .:

^■ 3-benzylidene camphor derivatives, preferably 3- (4-methylbenzylidene) camphor, 3-benzylidene camphor;

^■ 4-aminobenzoic acid derivatives, preferably 4- (dimethylamino) benzoic acid (2-ethyl hexyl) ester, 4- (dimethylamino) benzoesäureamylester;

2,4,6-trianilino (p-carbo-2'-ethyl-1'-hexyloxy) -1,3,5-triazine;

^■ esters of benzalmalonic acid, preferably di-2-ethylhexyl 4-methoxybenzalmalonate;

^■ esters of cinnamic acid, preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-meth- oxyzimtsäureisopentylester;

^■ Derivatives of benzophenone, preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone

^■ as well as UV-bound polymers.

Advantageous water-soluble UV-B filter substances are z. B .:

^■ salts of 2-phenylbenzimidazole-5-sulfonic acid, such as its sodium, potassium or its triethanolammonium salt, and the sulphonic acid itself;

^■ sulfonic acid derivatives of 3-benzylidenecamphor, such as. B. 4- (2-oxo-3-bornylidenme- thyl) benzenesulfonic acid, 2-methyl-5- (2-oxo-3-bomylidenemethyl) sulfonic acid and salts thereof.

The list of said UV filters which can be used in the context of the present invention is of course not intended to be limiting. According to the invention, preparations which contain the active substance combinations according to the invention can be advantageously used with customary antioxidants.

Advantageously, the antioxidants are selected from the group consisting of amino acids (eg glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg urocaninic acid) and derivatives thereof, peptides such as D, L-carnosine, D-carnosine, L-carnosine. Carnosine and its derivatives (eg anserine), carotenoids, carotenes (eg α-carotene, β-carotene, lycopene) and their derivatives, aurothioglucose, propylthiouracil and other thiols (eg thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, γ-linoleyl, cholesteryl and glyceryl esters) and their salts, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and their derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) and sulfoximinverbindungen (eg Buthioninsulfoximine, Homocysteinsulfoximin, Buthioninsulfone, penta-, hexa-, Heptathioninsulfoximin) in very low tolerated dosages (eg p mol to μΓΤΐοΙ / kg), further (metal) chelators (e.g. α-hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), α-hydroxy acids (eg citric acid, lactic acid, malic acid), humic acid, bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives (eg γ-linolenic acid , Linoleic acid, oleic acid), folic acid and its derivatives, alaninediacetic acid, flavonoids, polyphenols, catechins, vitamin C and derivatives (eg ascorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate), tocopherols and derivatives (eg vitamin E acetate), and coniferyl benzoate Benzoin, rutinic acid and derivatives thereof, ferulic acid and its derivatives, butylhydroxytoluene, butylhydroxyanisole, nordihydroguaiacetic acid, nordihydroguiaretic acid, trihydroxybutyrrophenone, uric acid and its derivatives, mannose and its derivatives, zinc and its derivatives (eg ZnO, ZnSu4) selenium and derivatives thereof ( eg selenium methionine), stilbenes and their derivatives (eg stilbene oxide, trans-stilbene oxide) and the According to the invention, suitable derivatives (salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids) of said active substances.

The amount of antioxidants (one or more compounds) in the preparations is preferably 0.001 to 10 wt .-%, more preferably 0.1 to 5 wt .-%, in particular 0.1 to 3 wt .-%, based on the total weight the preparation. The prophylaxis or the cosmetic or dermatological treatment with the cosmetic or topical dermatological preparations with an effective content of N- (4-amino-2-methylquinolin-6-yl) -2 - ((4-ethylphenoxy) methyl) benzamide is carried out in the usual way, namely that the cosmetic or topical dermatological preparations having an effective content of N- (4-amino-2-methylquinolin-6-yl) -2 - ((4-ethylphenoxy) methyl) benzamide on the affected Skin is applied.

Advantageously, N- (4-amino-2-methylquinolin-6-yl) -2 - ((4-ethylphenoxy) methyl) benzamide can be incorporated into conventional cosmetic and dermatological preparations which may be in various forms. So they can e.g. a solution, a water-in-oil (W / O) or oil-in-water (O / W) type emulsion, or a multiple emulsions, such as water-in-oil-in-water (W / O / W) or oil-in-water-in-oil (O / W / O), a hydrodispersion or lipodispersion, a gel, a solid stick or even an aerosol.

Emulsions according to the invention for the purposes of the present invention, e.g. in the form of a cream, a lotion, a cosmetic milk are advantageous and contain e.g. Fats, oils, waxes and / or other fatty substances, as well as water and one or more emulsifiers, as they are commonly used for such a type of formulation.

The aqueous phase of the preparations according to the invention may advantageously contain customary cosmetic auxiliaries, for example alcohols, in particular those of low C number, preferably ethanol.

It is also possible and advantageous in the context of the present invention to incorporate the active ingredient used according to the invention into aqueous systems or surfactant preparations for cleaning the skin and hair.

Of course, it is known to the person skilled in the art that sophisticated cosmetic compositions are generally not conceivable without the customary auxiliaries and additives. The cosmetic preparations according to the invention can therefore contain cosmetic auxiliaries as are customarily used in such preparations, for example preservatives, bactericides, deodorizing substances, antiperspirants, insect repellents. lentia, vitamins, antifoaming agents, dyes, coloring pigments, thickeners, emollients, moisturizing and / or moisturizing substances, fats, oils, waxes or other common ingredients of a cosmetic formulation, such as alcohols, polyols, polymers, foam stabilizers, Electrolytes, organic solvents or silicone derivatives.

Mutatis mutandis, corresponding requirements apply to the formulation of medical preparations.

Medicinal topical compositions according to the present invention usually contain one or more drugs in effective concentration. For the sake of simplicity, reference is made to the clear distinction between cosmetic and medical use and corresponding products to the statutory provisions of the Federal Republic of Germany (for example, Cosmetics Regulation, Food and Medicines Act).

The oil phase of the emulsions of the present invention is advantageously selected from the group of esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids having a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols a chain length of 3 to 30 carbon atoms, from the group of esters of aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols having a chain length of 3 to 30 carbon atoms. Such ester oils can then advantageously be selected from the group of isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononyl isononanoate, 2-ethylhexyl palmitate, 2-ethylhexyl laurate, 2-hexyldecyl stearate, 2 Octyldodecyl palmitate, oleyl oleate, oleyl erucate, erucyl oleate, erucyl erucate and synthetic, semi-synthetic and natural mixtures of such esters, eg Jojoba oil.

Furthermore, the oil phase can be advantageously selected from the group of branched and unbranched hydrocarbons and waxes, the silicone oils, the dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and the fatty acid triglycerides, namely the triglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids of a chain length of 8 to 24, in particular in particular 12 - 18 carbon atoms. The fatty acid triglycerides can for example be selected advantageously from the group of synthetic, semisynthetic and natural oils, for example olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil, argan oil, jojoba oil, macadamia oil, Olus Oil, shea butter , Cocoa butter and the like more.

Any mixtures of such oil and wax components are also advantageous to use in the context of the present invention. It may also be advantageous, if appropriate, to use waxes, for example cetyl palmitate, as the sole lipid component of the oil phase.

Preparations according to the invention present as emulsions advantageously contain one or more hydrocolloids. These hydrocolloids can be advantageously selected from the group of gums, polysaccharides, cellulose derivatives, layered silicates, polyacrylates, carbomers, acrylates / C 10-30 alkyl acrylate crosspolymer, and / or other polymers.

Hydrogel preparations according to the invention contain one or more hydrocolloids. These hydrocolloids can be advantageously selected from the aforementioned group.

Efficacy tests:

For the vitality assay, dermal fibroblasts were treated for 24 h with active ingredients / drug combinations in the cell culture medium and in the meantime provided with BrdU (5-bromo deoxy-uridine). The cells take up this unnatural nucleic acid detectable by fluorescence detection and integrate it into the newly synthesized genetic material during cell division. Thus, the subsequently measured fluorescence intensity of the cell lawn after 24 h is ultimately a measure of the cell division rate during drug treatment. Thus, the influence of the respective active ingredients on the cell vitality can be deduced.

The lipid assay is performed on subcutaneous adipocytes. Pre-adipocytes are seeded in cell culture dishes and differentiated into adipocytes. This is followed by a weeklong Drug treatment during which the cells synthesize lipids and store vesicularly. The total amount of lipid depending on drug effects is determined at the end of the culture period. For this purpose, the cell lawn is stained with the lipophilic fluorescent dye AdipRed and then quantified by fluorescence spectroscopy.

The third assay performed is the LDH (lactate dehydrogenase) cytotoxicity assay. In this assay, the metabolic enzyme LDH is detected from the cell supernatant of the cell lawn by adding a substrate for the enzyme to the cell culture supernatant. After its implementation, a color change occurs and this is detected photometrically. The degree of color change correlates with the amount of LDH in the cell culture supernatant. LDH, however, is an intracellular enzyme, and can only be induced by cell damage, e.g. get into the media supernatant of cell cultures by toxic substances and simultaneous damage to the cell membrane.

For all assays, the active ingredients were dissolved as 1000x stock in DMSO at 10 mg / ml and were diluted for use according to 1: 1000 in the respective cell culture medium.

Results:

Glycyrrhitic acid 0.10

Niacinamide 0.20

Magnesium ascorbyl phosphate 0.10

Licorice Root Extract 0.10

Sea salt 0,05

Bis-Ethylhexyloxyphenol Methoxyphenyl

Triazine 1, 00

Octocrylene 9.00 4.00 2.00

Butyl Methoxydibenzoylmethane 5.00 3.50 2.00

Ethylhexyl salicylate 5.00 3.00

Sodium hydroxide q.s. q.s. q.s. q.s.

Water ad 100 ad 100 ad 100 ad 100

Claims

claims

1 . Cosmetic use of N- (4-amino-2-methylquinolin-6-yl) -2 - ((4-ethylphenoxy) methyl) benzamide for the treatment and / or prophylaxis of the symptoms of intrinsic and / or extrinsic skin aging and for treatment and Prophylaxis of the harmful effects of ultraviolet radiation on the skin.

2. Use according to claim 1, characterized in that it contains 0.001-10 wt .-% of N- (4-amino-2-methylquinolin-6-yl) -2 - ((4-ethylphenoxy) methyl) benzamide, based on the total weight of the preparations.

3. N- (4-amino-2-methylquinolin-6-yl) -2 - ((4-ethylphenoxy) methyl) for treatment

and / or prophylaxis of the symptoms of intrinsic and / or extrinsic skin aging and for the treatment and prophylaxis of the deleterious effects of ultraviolet radiation on the skin.

4. N- (4-amino-2-methylquinolin-6-yl) -2 - ((4-ethylphenoxy) methyl) according to claim 3, in dermatological preparations, characterized in that this 0.001-10% by weight of N - (4-amino-2-methylquinolin-6-yl) -2 - ((4-ethylphenoxy) methyl) benzamide, based on the total weight of the preparations.